USD 33.43 billion
Report ID:
SQMIG35H2165 |
Region:
Global |
Published Date: April, 2025
Pages:
219
|Tables:
119
|Figures:
77
Global Plasma Fractionation Market size was valued at USD 33.43 billion in 2023 and is poised to grow from USD 36.2 billion in 2024 to USD 68.52 billion by 2032, growing at a CAGR of 8.3% during the forecast period (2025-2032).
One method used to extract specific amounts from a mixture is called fractionation. Additionally, the fluid component of blood is called plasma, and it can be separated to produce other plasma derivatives such immunoglobulins and albumin. These generated plasma products are used to treat a variety of blood plasma-related illnesses due to their therapeutic properties. For example, coagulation factor VIII, a plasma product, is used to treat and prevent haemophilia. It is often used during surgical operations to prevent excessive blood loss. Likewise, immunoglobulins are used to address immunological deficits, both primary and secondary.
The main driver of the global plasma fractionation market's growth is the world's ageing population, which is more likely to be susceptible to rare diseases that call for the usage of plasma derivatives. Additionally, the market for plasma fractionation is growing due to the increased use of immunoglobulins and alpha-1-antitrypsin in many medical fields globally. Additionally, a significant element driving the market's expansion is the global spike in plasma collection facilities. The market for plasma fractionation is also growing because of the government's supportive initiatives to raise knowledge about the usage of goods generated from plasma. The market's expansion is, however, limited by the high cost of items derived from plasma.
Market snapshot - 2025-2032
Global Market Size
USD 33.43 billion
Largest Segment
Immunoglobulins
Fastest Growth
Albumin
Growth Rate
8.3% CAGR
To get more reports on the above market click here to Buy The Report
Global Plasma Fractionation Market is segmented by Product, Application, End User and region. Based on Product, the market is segmented into Immunoglobulins, Coagulation Factor Concentrates, Albumin, Protease Inhibitors and Other Plasma Products. Based on Application, the market is segmented into Neurology, Immunology, Hematology, Critical care, Pulmonology, Hemato-Oncology, Rheumatology and Other Applications. Based on End User, the market is segmented into Hospitals and Clinics, Clinical Research Laboratories and Academic institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
As per categorization by product, the plasma fractionation market is classified as immunoglobulins, coagulation factor concentrates, albumin, protease inhibitors and other plasma products. Among these, immunoglobulins earned the largest share and continue to dominate the market. The global plasma fractionation market is experiencing a notable change with the introduction of new products, particularly immunoglobulin products which can be attributed to the innovation in the purification technologies and rise in the therapy's curative of autoimmune diseases and immunodeficiencies. This market is evidently led by immunoglobulins given the effectiveness, safety and variety of conditions that they can address – which further underpins their indispensable role in the health care sector.
Albumin is poised to be the fastest-growing segment in the global plasma fractionation market due to its diverse applications in critical care, including fluid resuscitation, liver disease treatment, and as a stabilizer in drug formulations. The growing incidence of chronic diseases along with the increasing number of surgical operations are active factors in the growth of the albumin products market. Furthermore, improvement in manufacturing processes and better emphasis on the development of therapeutic uses helps raise the market attractiveness of albumin and makes it one of the main components expected to grow in the plasma fractionation market.
Cryoprecipitation is gaining traction in the global plasma fractionation market due to innovations in freeze-thaw processes that enhance yield and quality. Its dominance stems from its critical role in treating bleeding disorders, such as hemophilia, and its ability to provide concentrated clotting factors, making it essential in emergency and surgical care.
Due to efficiency and accuracy in separating and purifying plasma proteins, it is expected that Chromatography will emerge as the fastest growing technique in the global plasma fractionation market. The growing need for advanced immunoglobulin and albumin products, moisture content in the albumin, most importantly, chromatographic technologies are said to enhance the yield and lower the processing time. Given that healthcare systems are right now oriented towards improved production techniques without compromising on the safety and effectiveness of the products, the strategy behind the use of chromatography in boosting productivity and facilitating the use of new products will guarantee its demand in the foreseeable future.
To get detailed analysis on other segments, Request For Free Sample Report
Owing to the presence of an advanced healthcare system, extensive research and development activities, and high expenditure on biopharmaceuticals, North America holds the largest global plasma fractionation market share. Health care services and the concept of personalized medicine within these advanced health care systems also contribute to the market for plasma-based medical products, especially immunoglobins and albumin. Moreover, the existence of essential contributors to the market coupled with strong regulatory policies helps in ensuring the safety and effectiveness of the products. The calling burden of chronic diseases is on the rise, and plasma therapies are becoming popular among both practitioners and patients which also serves to enhance the growth of the market in North America, further solidifying its position in the global plasma fractionation market outlook.
Europe is the most progressive region walking the global plasma fractionation market, due to the booming need for efficacious therapeutic plasma products and improvement in fractionation processes. This region has milder regulatory approach towards plasma therapies which enhances innovation in the region. Moreover, the aging population is intensifying the demand for treatment as well as the increase of autoimmune diseases and hemophilia. Additionally, strong collaborations between academic institutions and biopharmaceutical companies enhance research and development efforts, facilitating the introduction of new products. This dynamic environment positions Europe as a leader in the expanding plasma fractionation landscape.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Rising Demand for Immunoglobulins:
Technological Advancements in Fractionation Processes:
High Production Costs:
Regulatory Challenges:
Request Free Customization of this report to help us to meet your business objectives.
The plasma fractionation market remains controlled by both historical firms and new entrants which are boosting growth and creativity. Examples of major scion companies are Grifols, CSL Behring, Takeda Pharmaceutical Company, and Octapharma, whose focus is on improving product development and industrial expansion within international borders. These firms invest significantly in research and development to improve processing technologies and product efficacy, positioning themselves strategically to meet the increasing demand for plasma-derived therapies worldwide.
Rising Demand for Specialty Plasma Products:
Advancements in Fractionation Technologies:
SkyQuest's ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, in conclusion, the global plasma fractionation market is experiencing robust growth driven by rising demand for plasma-derived products, particularly immunoglobulins and albumin. Technological advancements in fractionation processes and increased plasma collection facilities further support this expansion.
Even with difficulties like high production costs and strict regulations, major companies are innovating to improve the quality and availability of the products. While North America and Europe remain at the forefront of the market, there will be a regional focus on plasma fractionation research, development, applications, and patient management that will define the future of plasma fractionation, ensuring effective therapies for numerous diseases.
Report Metric | Details |
---|---|
Market size value in 2023 | USD 33.43 billion |
Market size value in 2032 | USD 68.52 billion |
Growth Rate | 8.3% |
Base year | 2024 |
Forecast period | 2025-2032 |
Forecast Unit (Value) | USD Billion |
Segments covered |
|
Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
Companies covered |
|
Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Plasma Fractionation Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Plasma Fractionation Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Plasma Fractionation Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Plasma Fractionation Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
Plasma Fractionation Market size was valued at USD 33.43 Billion in 2023 and is poised to grow from USD 36.2 Billion in 2024 to USD 68.52 Billion by 2032, growing at a CAGR of 8.3% during the forecast period (2025-2032).
The plasma fractionation market remains controlled by both historical firms and new entrants which are boosting growth and creativity. Examples of major scion companies are Grifols, CSL Behring, Takeda Pharmaceutical Company, and Octapharma, whose focus is on improving product development and industrial expansion within international borders. These firms invest significantly in research and development to improve processing technologies and product efficacy, positioning themselves strategically to meet the increasing demand for plasma-derived therapies worldwide. 'CSL Behring (Australia)', 'Grifols (Spain)', 'Octapharma (Switzerland)', 'Kedrion (Italy)', 'China Biologic Products Holdings (China)', 'Sanquin (Netherlands)', 'Bio Products Laboratory (UK)', 'Japan Blood Products Organization (Japan)', 'LFB Group (France)', 'Shanghai RAAS Blood Products (China)', 'Green Cross Corporation (South Korea)', 'Baxter International Inc. (US)', 'Takeda Pharmaceutical Company Limited (Japan)', 'Beijing Tiantan Biological Products (China)', 'Biotest AG (Germany)', 'China National Pharmaceutical Group Co. (Sinopharm) (China)', 'GC Pharma (South Korea)', 'ADMA Biologics (US)', 'Emergent BioSolutions (US)', 'Renishaw plc (UK)', 'HP Inc. (USA)'
The rising number of cases relating to diseases related to immunodeficiency disorders and autoimmune conditions stands as an important factor fueling the growth of the global plasma fractionation market. Healthcare professionals use Immunoglobulins for these purposes which causes the demand for these products to spike. This trend stimulates creativity and growth in the development and emergence of plasma-based therapeutic products purification processes and manufacturing.
There is rising demand for specialized plasma products like immunoglobulins and clotting factor concentrates in the global plasma fractionation market. This is due to the increasing incidence of chronic and autoimmune disorders which requires detailed and effective treatment methods for patients.
Owing to the presence of an advanced healthcare system, extensive research and development activities, and high expenditure on biopharmaceuticals, North America holds the largest global plasma fractionation market share. Health care services and the concept of personalized medicine within these advanced health care systems also contribute to the market for plasma-based medical products, especially immunoglobins and albumin. Moreover, the existence of essential contributors to the market coupled with strong regulatory policies helps in ensuring the safety and effectiveness of the products. The calling burden of chronic diseases is on the rise, and plasma therapies are becoming popular among both practitioners and patients which also serves to enhance the growth of the market in North America, further solidifying its position in the global plasma fractionation market outlook.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
Report ID: SQMIG35H2165
[email protected]
USA +1 351-333-4748